Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.

Kenvue Inc.

Cullen Capital Management, LLC disclosed the sale of 6,565,339 shares of Kenvue (KVUE -0.77%) for the period ended Q2 2025. The transaction was valued at an estimated $149.46 million.

Cullen Trims KVUE Stake With $149.5M Share Sale

Kenvue faces near-term headwinds from Tylenol-autism allegations, macro uncertainty, and segment underperformance, but offers long-term income potential. Recent leadership changes and a focus on core brands and technology could drive future improvements, though execution risk remains amid economic challenges. KVUE's forward dividend yield near 5% and a solid balance sheet make it attractive for income-focused investors despite limited near-term upside.

Kenvue: Trump-Era Volatility Presents A More Attractive Opportunity, But Headwinds Remain

A pair of United States lawmakers sold shares in Tylenol's parent company, Kenvue (NYSE: KVUE), just days before President Donald Trump made controversial remarks linking the painkiller to autism.

These U.S. politicians dumped Tylenol maker shares before Trump's autism warning

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.

What Moved Markets This Week

The CEO behind Tylenol thought he'd found a way to work with the Trump administration. Then everything went off the rails.

U.S. President Donald Trump on Friday repeated his call for pregnant women and young children to stop using popular pain medication Tylenol, defying widespread criticism from medical groups, and offered further healthcare advice not backed by science.

Trump repeats Tylenol and vaccine claims, defying medical community outcry

The article highlights the top ten S&P Hi-Yield Aristocrats for September, with nine stocks offering attractive yields and fair pricing for dividend investors. Analyst forecasts project potential net gains of 21.59% to 66.98% by September 2026 for these high-yield 'dog' stocks, with average risk 31% below the market. Five lowest-priced Hi-Yield Aristocrats—AMCR, FLO, PRGO, BEN, RHI—are expected to outperform the higher-priced group, reflecting the classic 'Dogs of the Dow' strategy.

51 September S&P Hi-Yield Aristocrats: 5 To Buy

RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next?

Families appealing the dismissal of their lawsuits alleging that Kenvue's Tylenol or generic versions of the pain-relief medication caused their children's autism are asking an appeals court to consider President Donald Trump's new advice that pregnant women avoid the pain killer as it decides whether to revive their lawsuits.

Attorneys urge court overseeing Tylenol autism lawsuits to consider Trump administration's stance

The heads of key health agencies advocated for putting the emphasis on leucovorin, but Kennedy became convinced that he had a moral duty to get the word out about the risk of acetaminophen.

RFK Jr.'s team wanted to tout an autism therapy. But a meeting with Tylenol's maker convinced the U.S. health secretary to put the emphasis on acetaminophen

Kenvue shares have dropped 17% following reports linking Tylenol to autism, creating a potential long-term buying opportunity. The market reaction appears to be an overreaction, as Tylenol accounts for roughly $1 billion in sales and a fraction of Kenvue's total revenue. The current valuation implies an unrealistic 40%+ decline in Tylenol sales, which seems excessive given the actual business impact.

Kenvue: This Too Shall Pass

Kenvue stock is rebounding. It may be a largely a case of things-could've-been- worse.

Kenvue Stock Recoups Losses After Trump Links Tylenol to Autism

The Trump administration on Monday drew an unproven link between autism and pregnant women's use of acetaminophen, the active ingredient in one of the world's most common over-the-counter pain relievers, Kenvue's Tylenol. CNBC's Angelica Peebles explains.

Trump links autism to Tylenol ingredient use during pregnancy — here's what to know

Shares of Tylenol maker Kenvue bounced back sharply at the opening bell Tuesday, a day after President Donald Trump promoted unproven and, in some cases, discredited ties between Tylenol, vaccines, and autism.

Tylenol maker Kenvue rebounds after Trump spreads unproven claims

President Donald Trump on Monday used the platform of the presidency to promote unproven and in some cases discredited ties between Tylenol, vaccines and autism as his administration announced a wide-ranging effort to study the causes of the complex brain disorder.“Don't take Tylenol,” Trump instructed pregnant women around a dozen times during the unwieldy White House news conference, also urging mothers not to give their infants the drug, known by the generic name acetaminophen in the U.S. or paracetamol in most other countries.

How Trump is spreading unproven information about Tylenol, autism, and vaccines

Kenvue Inc (NYSE:KVUE) stock is up 3.9% to trade at $17.62 at last check, erasing some of yesterday's losses that followed the Trump administration connection between the use of  acetaminophen -- the active ingredient of the company's  Tylenol pain drug  -- in pregnancy and autism.

Pharmaceutical Stock Bounces Off Record Lows

I'm initiating Kenvue Inc. with a Buy after a sharp selloff following President Donald Trump's remarks on Monday linking Tylenol with autism. KVUE's profitability, with gross margins above 58% and EBITDA margins over 23%, provides resilience against legal and headline risks. Despite Self Care sales weakness and ongoing litigation concerns, Tylenol continues to gain market share and new product launches are underway.

Tylenol: Kenvue's Sobering Reality

U.S. President Donald Trump on Monday linked autism to childhood vaccines and the use of popular pain medication Tylenol by women when pregnant, elevating claims not backed by scientific evidence to the forefront of U.S. health policy.

QUOTE BOX Global reaction to Trump's unproven claim about Tylenol's link to autism

CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news on the Trump administration's announcement linking acetaminophen taken during pregnancy to autism.

Shares of Kenvue rebound today after Trump admin ties use of acetaminophen to autism

Kenvue (KVUE) rallied Tuesday morning despite the Trump administration linking Tylenol to autism. Diane King Hall notes that analyst commentary may have helped the stock's upward trajectory.

KVUE Rebounds Against Trump Admin, BA International Boost, AZO Earnings Miss

Real-time stock quote and overview for KVUE